| 000 | 00000nam 2200000za 4500 |
| 001 | 9.573626 |
| 003 | CaOODSP |
| 005 | 20210624183805 |
| 007 | cr ||||||||||| |
| 008 | 150406t19981997cn ad|||o f000 0 eng d |
| 020 | |a0-662-26385-5 |
| 040 | |aCaOODSP|beng |
| 043 | |an-cn--- |
| 086 | 1 |aH42-2/67-12-1997E-PDF |
| 245 | 00|aGeneral considerations for clinical trials |h[electronic resource]. |
| 246 | 3 |iAt head of title: |aICH Harmonised Tripartite guideline : |bInternational Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use |
| 260 | |aOttawa : |bTherapeutic Products Directorate, Health Canada. |c1998, c1997. |
| 300 | |aii, 22 p. : |bill. |
| 490 | 1 |aTherapeutic Products Directorate guidelines |
| 500 | |a"ICH Harmonised Tripartite guideline, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use." |
| 500 | |aIncorrect catalogue number (H42-2/67-12-1997IN) recorded in this electronic publication. |
| 590 | |a12-14-Supp|b2012-04-10 |
| 710 | 1 |aCanada.|bHealth Canada. |bTherapeutic Products Directorate. |
| 775 | 08|tConsidérations générales relatives aux études cliniques : |w(CaOODSP)9.603737 |
| 776 | 0#|tICH harmonized tripartite guideline: general consideration for clinical trials : |w(CaOODSP)9.614224 |
| 830 | #0|aTherapeutic Products Directorate guidelines.|w(CaOODSP)9.506920 |
| 856 | 40|ahttp://publications.gc.ca|qPDF|s105 KB|uhttps://publications.gc.ca/collections/Collection/H42-2-67-12-1997E.pdf |